ライフサイエンスコーパス: radiation therapy

1 ts in favor of chemotherapy (with or without radiation therapy).

2 III FHWT were treated with Regimen DD4A and radiation therapy.

3 s the basis for recommendations for adjuvant radiation therapy.

4 sure the safe delivery of selective internal radiation therapy.

5 iomics features changed significantly during radiation therapy.

6 do some other approaches such as palliative radiation therapy.

7 scars or adverse reactions after surgery or radiation therapy.

8 andard regimens; > 90% of patients can avoid radiation therapy.

9 nced cervical cancer treated with chemo- and radiation therapy.

10 for patients with thoracic cancer receiving radiation therapy.

11 ues or for participating in tumor control by radiation therapy.

12 ey facet of precision medicine, surgery, and radiation therapy.

13 future targeted therapy in conjunction with radiation therapy.

14 totally resected EPN_PFA, even with adjuvant radiation therapy.

15 evasion, and resistance to chemotherapy and radiation therapy.

16 dard treatment options including surgery and radiation therapy.

17 cancer and the tissue-specific responses to radiation therapy.

18 ution on cell survival outcomes of simulated radiation therapy.

19 eting family needs 6 months after completing radiation therapy.

20 of these novel regimens in combination with radiation therapy.

21 of these novel regimens in combination with radiation therapy.

22 [95% CI, 41.04-48.17]) influence the use of radiation therapy.

23 also been found to enhance tumor response to radiation therapy.

24 sms occurred mainly in patients treated with radiation therapy.

25 ation therapy or three-dimensional conformal radiation therapy.

26 l agents, surgery, or definitive or adjuvant radiation therapy.

27 limit late vascular complications caused by radiation therapy.

28 atients receiving implant reconstruction and radiation therapy.

29 herapy toward chemotherapy with a decline in radiation therapy.

30 rwent PET/CT in 2006-2013 before systemic or radiation therapy.

31 however, GSCs are resistant to conventional radiation therapy.

32 adopted regimens such as chemotherapy and/or radiation therapy.

33 thereby increasing the therapeutic ratio of radiation therapy.

34 mical relapse after surgery or external-beam radiation therapy.

35 n decisions about surgery, chemotherapy, and radiation therapy.

36 y allow for higher and more regular doses of radiation therapy.

37 mproved surgical strategies and systemic and radiation therapy.

38 e had expanders removed for infection before radiation therapy.

39 recurrence of prostate cancer after primary radiation therapy.

40 m delivery planning, and intensity-modulated radiation therapy.

41 cristine, dactinomycin, and doxorubicin) and radiation therapy.

42 tissue damage and improving tumor control in radiation therapy.

43 y) or daily placebo tablets during and after radiation therapy.

44 ion associated with short-term relapse after radiation therapy.

45 quent surgery with adjuvant chemotherapy and radiation therapy.

46 had good EFS/overall survival with DD4A and radiation therapy.

47 alone is now recommended for low-emetic-risk radiation therapy.

48 inadequate follow-up (<1 year) and previous radiation therapy.

49 e chemotherapy with or without external beam radiation therapy (21.0%).

50 nd three-dimensional conformal external beam radiation therapy (3D-CRT) have not been compared prospe

51 ents receiving autologous reconstruction and radiation therapy, 4.1 for patients receiving implant re

52 The most common treatment type is radiation therapy (57.9% [95% CI, 57.4%-58.4%]), followe

53 nderwent 2 PET/CT scans (1-3 d apart) before radiation therapy: a 3-min static (18) F-FDG and a dynam

54 iopsy, chemotherapy, or internal or external radiation therapy, according to the clinical schedule; p

55 incristine, and prednisone (58%), with local radiation therapy added in 21%.

56 ldhood ALL has eliminated the use of cranial radiation therapy, adolescent survivors treated with che

57 everal strategies to improve the efficacy of radiation therapy against hepatocellular carcinoma (HCC)

58 overall survival than did those who received radiation therapy alone (13.3 vs. 7.8 years; hazard rati

59 ril 15, 2001, were identified, randomized to radiation therapy alone or radiation therapy followed by

60 Patients were randomly assigned to radiation therapy alone or to radiation therapy followed

61 iation therapy than among those who received radiation therapy alone.

62 ree survival, but not overall survival, than radiation therapy alone.

63 herapy versus 21% in the group that received radiation therapy alone; the corresponding rates of over

64 mly assigned to receive radiation therapy or radiation therapy and 6 months of ADT.

65 ancer that are resistant to chemotherapy and radiation therapy and are responsible for tumor reoccurr

66 nformation and guidance on treatment such as radiation therapy and chemotherapy after surgery.

67 Conversely, radiation therapy and chemotherapy induce DNA damage to

68 f a multidisciplinary approach that includes radiation therapy and chemotherapy, plays a central part

69 cer development and cancer outcome following radiation therapy and chemotherapy.

70 She received adjuvant radiation therapy and initiated letrozole, with excellen

71 e data support the feasibility of its use in radiation therapy and preoperative planning and assessin

72 l of 0.2 to 4.0 ng per milliliter to undergo radiation therapy and receive either antiandrogen therap

73 aging as prognostic, overall, and in primary radiation therapy and surgery subgroups, but ultimately

74 jection were detected in tumors treated with radiation therapy and TGFbeta blockade in combination bu

75 lts suggest radiomics features change due to radiation therapy and their values at the end of treatme

76 LMICs do not have adequate access to quality radiation therapy and this gap is particularly pronounce

77 years), 22 patients (92%) had received prior radiation therapy, and 15 patients (63%) had received tw

78 nts receiving implant reconstruction without radiation therapy, and 2.8 for patients receiving implan

79 Although surgery, radiation therapy, and chemotherapy have significantly i

80 ommended adjuvant chemotherapy, postsurgical radiation therapy, and endocrine therapy.

81 mended adjuvant chemotherapy, postmastectomy radiation therapy, and endocrine therapy.

82 Primary treatments included local resection, radiation therapy, and enucleation.

83 tive therapy, chemotherapy, clinical trials, radiation therapy, and surgery) was conducted.

84 CH was associated with increased age, prior radiation therapy, and tobacco use.

85 Though a variety of cytotoxic drugs and radiation therapies are currently available in clinical

86 ng of locoregional therapies and systemic or radiation therapies are likely to add additional options

87 ors of childhood cancer treated with cranial radiation therapy are at risk for subsequent CNS tumors.

88 etween 1988 and 2011 and who did not receive radiation therapy as part of the first course of treatme

89 inal brachytherapy is as effective as pelvic radiation therapy at preventing vaginal recurrence and i

90 ne (also called CCNU), and vincristine after radiation therapy at the time of initial diagnosis resul

91 ted with curative-intent intensity-modulated radiation therapy between August 2011 and May 2012 were

92 th stage III NSCLC treated definitively with radiation therapy between January 2008 and January 2013.

93 Intratumoral radiation therapy - 'brachytherapy' - is a highly effect

94 absorbance effects of high-energy photons in radiation therapy by increasing the emission of Auger-ph

95 No difference in the use of surgery or radiation therapy by location was found.

96 Radiation therapy can induce immune responses to model a

97 involves a regiment of radical prostectomy, radiation therapy, chemotherapy and hormonal therapy.

98 sease was characterized as surgical therapy, radiation therapy, chemotherapy, or any form thereof acr

99 natorial approaches with targeted therapies, radiation therapy, chemotherapy, or other immune checkpo

100 ression, and overall survival under clinical radiation therapy conditions were observed in a human pa

101 Information on cranial radiation therapy (CRT) doses and parameters of delivery

102 assess response to combined chemotherapy and radiation therapy (CRT) in patients with rectal cancer b

103 CR) to neoadjuvant combined chemotherapy and radiation therapy (CRT) in patients with rectal cancer.

104 L), especially those treated without cranial radiation therapy (CRT).

105 ated and analyses were stratified by cranial radiation therapy (CRT; CRT or no CRT).

106 or CPS+EG scores >/=3, use of postmastectomy radiation therapy decreases the likelihood of LRR after

107 on of the bladder tumor alone, or < 50 Gy of radiation therapy delivered to the bladder were included

108 eceipt of radical cystectomy or >/= 50 Gy of radiation therapy delivered to the bladder, affects over

109 Thus, selective internal radiation therapy demands an expert multidisciplinary te

110 elevant for research in targeting agents and radiation therapy dose escalation.

111 doxorubicin dose >/= 300 mg/m(2) and cardiac radiation therapy dose greater than 30 Gy were independe

112 Radiation therapy dose was categorized into 4 groups: gr

113 ning age at primary cancer, sex, and cranial radiation therapy dose yielded an area under the curve o

114 nts and inhibitors, in photodynamic therapy, radiation therapy, drug/gene delivery, biosensing, and b

115 linical trials, dose-escalated external-beam radiation therapy (EBRT) for prostate cancer resulted in

116 rials comparing dose-escalated external beam radiation therapy (EBRT) with brachytherapy in men with

117 IIE) was commonly treated with external beam radiation therapy (EBRT) with or without chemotherapy, w

118 ed with radical prostatectomy, external beam radiation therapy (EBRT), and active surveillance.

119 er undergoing outpatient chemotherapy and/or radiation therapy enrolled in this questionnaire-based s

120 r survivors and enable more effective use of radiation therapies, especially in children.

121 ed, randomized to radiation therapy alone or radiation therapy followed by 6 months of androgen depri

122 ly assigned to radiation therapy alone or to radiation therapy followed by six cycles of combination

123 During the early decades of radiation therapy for breast cancer, local control of di

124 after preoperative combined chemotherapy and radiation therapy for cervical carcinoma and evaluate th

125 ded to assess benefits and risks of adjuvant radiation therapy for each patient with N2 disease.

126 "The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evide

127 ASCO endorsed the ASTRO guideline on radiation therapy for glioblastoma and added qualifying

128 Methods The ASTRO guideline on radiation therapy for glioblastoma was reviewed for deve

129 TRO) produced an evidence-based guideline on radiation therapy for glioblastoma.

130 All patients who underwent radiation therapy for localized prostate cancer between

131 Tumor regression after radiation therapy for melanomas was associated with decr

132 radiation (IR) reduces the effectiveness of radiation therapy for non-small cell lung cancer (NSCLC)

133 erapeutic value of cytoreductive surgery and radiation therapy for posterior fossa ependymoma after a

134 2011, 30 men with biochemical failure after radiation therapy for prostate cancer provided written i

135 genomic risk model for deciding on adjuvant radiation therapy for prostate cancer treated with radic

136 oMT readily occurs in the human rectum after radiation therapy for rectal adenocarcinoma.

137 Despite the effectiveness of surgery or radiation therapy for the treatment of early-stage prost

138 reviews and a search for studies related to radiation therapy found no additional randomized control

139 chemotherapy utilization with a decrease in radiation therapy from 1975 to 2010.

140 patients treated with stereotactic ablative radiation therapy from 2005 to 2013 were analyzed.

141 logic advance, analogous to the evolution in radiation therapy from conventional two- and three-dimen

142 Results DN:P ratio for the radiation therapy group was greater than that for the ot

143 c advances in multidrug systemic therapy and radiation therapy have already been adopted in the neoad

144 en (90)Y radioembolization and external-beam radiation therapy have been explained by citing differen

145 ology developments in diagnostic imaging and radiation therapy have elucidated parts of this enigma.

146 New developments in radiation therapy have improved recurrence-free survival

147 ciation with menopausal status, prior breast radiation therapy, hormonal treatment, breast density on

148 (CR) to AV-PC received 21-Gy involved-field radiation therapy (IFRT).

149 (STS) treated with preoperative image-guided radiation therapy (IGRT) to a reduced target volume.

150 robotic surgery, dynamic intensity-modulated radiation therapy, immunotherapy, and de-escalation tria

151 of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) after chemotherapy and pleur

152 -site cCR to IC received intensity-modulated radiation therapy (IMRT) 54 Gy with weekly cetuximab; th

153 re undergoing definitive intensity-modulated radiation therapy (IMRT) for localized prostate cancer.

154 Purpose Although intensity-modulated radiation therapy (IMRT) is increasingly used to treat l

155 -IVA cervical cancer treated with chemo- and radiation therapy in 2009-2013.

156 in 297 (17%) and mastectomy + postmastectomy radiation therapy in 744 (44%).

157 reatment protocol for (225)Ac-PSMA-617 alpha-radiation therapy in advanced-stage, metastatic castrati

158 Study XV, which omitted prophylactic cranial radiation therapy in all patients, completed comprehensi

159 nslational potential of SiGdNP for MR-guided radiation therapy in cancer treatment.

160 adioembolization compared with external-beam radiation therapy in gastrointestinal tissue.

161 Because cetuximab enhances the effect of radiation therapy in human papilloma virus-associated or

162 Because cetuximab enhances the effect of radiation therapy in human papilloma virus-associated or

163 TRO) produced an evidence-based guideline on radiation therapy in oropharyngeal squamous cell carcino

164 We investigated the effects of radiation therapy in p48(Cre);LSL-Kras(G12D) (KC) and p4

165 trolled trials investigating the efficacy of radiation therapy in patients with locally advanced unre

166 ed pancreatic cancer, the value and place of radiation therapy in the treatment algorithm is now unde

167 The role of radiation therapy in the treatment of patients with panc

168 al (Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Ly

169 26), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagno

170 89221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagno

171 m(2), and 35% of LSs had received additional radiation therapy involving the heart.

172 Purpose Radiation therapy is a critical component in the care of

173 Radiation therapy is a major treatment regimen for more

174 Microbeam radiation therapy is a novel preclinical technique, whic

175 Surveillance without adjuvant radiation therapy is a reasonable option for women witho

176 Radiation therapy is a staple approach for cancer treatm

177 Radiation therapy is administered to a significant numbe

178 cts on local and distant tumour control when radiation therapy is combined with immunotherapy.

179 Adjuvant radiation therapy is not recommended for patients with r

180 atients with stage IIIA N2 disease, adjuvant radiation therapy is not recommended for routine use.

181 Salvage radiation therapy is often necessary in men who have und

182 Radiation therapy is reserved for cases where surgery is

183 therapy with surgical resection and perhaps radiation therapy is used for localized disease.

184 dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT).

185 cteristics (no chemotherapy, splenectomy, or radiation therapy; male; attained age 28 years).

186 ent of DCIS without surgical intervention or radiation therapy may be advisable based on breast cance

187 on chemotherapy but unacceptable toxicities, radiation therapy may be offered as an alternative.

188 mmended for most patients (for some patients radiation therapy may be offered up front) with Eastern

189 iated enhancement of MMEJ in cells surviving radiation therapy may contribute to their radioresistanc

190 ioresistant cancer cells during fractionated radiation therapy may have implications in the developme

191 ic biomarker of biochemical recurrence after radiation therapy, metastasis and cancer-specific mortal

192 ose treated with more contemporary conformal radiation therapy methods.

193 AM is inert to immune activation, permitting radiation therapy monitoring.

194 Radiation therapy occurred at weeks 20 to 25 (primary) b

195 agents to act in conjunction with chemo- or radiation therapy of cancer cells.

196 Radiation therapy often accelerates atherosclerosis.

197 rway to understanding the powerful impact of radiation therapy on both breast cancer and critical org

198 vailable demonstrate a significant impact of radiation therapy on survival as well as disease control

199 ect surgery interaction with chemotherapy or radiation therapy on survival by using the National Canc

200 nvestigated within a randomized trial of the Radiation Therapy Oncology Group (RTOG 0129), which comp

201 ssociated with worse overall survival in the Radiation Therapy Oncology Group (RTOG) 0617 study.

202 The estimated cumulative 5 year incidence of Radiation Therapy Oncology Group (RTOG) grade 2 or worse

203 clinical target volumes (CTVs) based on the Radiation Therapy Oncology Group (RTOG) guidelines cover

204 ated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741).

205 The Radiation Therapy Oncology Group 9804 study identified g

206 atinum-based chemoradiotherapy (NRG Oncology Radiation Therapy Oncology Group [RTOG] 0129 and 0522).

207 tage III non-small-cell lung cancer (NSCLC) (Radiation Therapy Oncology Group [RTOG] 0617) showed a l

208 h the best 2-year OS and PFS achieved in any Radiation Therapy Oncology Group primary CNS lymphoma tr

209 suggest that the target volumes used in the Radiation Therapy Oncology Group RTOG-0630 (A Phase II T

210 gastrointestinal toxicity as defined by the Radiation Therapy Oncology Group was compared between th

211 Other treatments such as radiation therapy or anti-human epidermal growth recepto

212 125 controls, accounting for age, sex, prior radiation therapy or cisplatin treatment, Charlson Comor

213 Three-dimensional conformal radiation therapy or intensity-modulated radiation thera

214 y been treated by fractionated external beam radiation therapy or invasive brachytherapy.

215 tients were previously randomized to receive radiation therapy or radiation and 6 months of androgen

216 ancer (PC) were randomly assigned to receive radiation therapy or radiation therapy and 6 months of A

217 ction chemotherapy, without metastasis, then radiation therapy or stereotactic body radiotherapy may

218 ly fractions with either intensity-modulated radiation therapy or three-dimensional conformal radiati

219 Selective internal radiation therapy (or radioembolization) by intra-arteri

220 eated with surgical resection, chemotherapy, radiation therapy, or a combination of these treatments.

221 Watchful waiting or active surveillance, radiation therapy, or radical prostatectomy.

222 which we developed a 24-gene Post-Operative Radiation Therapy Outcomes Score (PORTOS).

223 y oncology specialists in medicine, surgery, radiation therapy, palliative care, nursing, and patholo

224 ts or PSA of more than 2.0 ng/mL for primary radiation therapy patients.

225 red with photon radiation (XRT), proton beam radiation therapy (PBRT) reduces dose to normal tissues,

226 eation in non-small cell lung cancer (NSCLC) radiation therapy planning by using pathology volumes as

227 s, prognostication, monitoring, and external-radiation therapy planning.

228 A Cox model identified receipt of radiation therapy plus chemotherapy and histologic findi

229 Patients who received radiation therapy plus chemotherapy had longer median ov

230 10 years was 51% in the group that received radiation therapy plus chemotherapy versus 21% in the gr

231 e cancer and death from prostate cancer than radiation therapy plus placebo.

232 data on the effectiveness of postmastectomy radiation therapy (PMRT) have led to changes in National

233 e Conventionally fractionated postmastectomy radiation therapy (PMRT) takes approximately 5 to 6 week

234 re are numerous challenges in implementing a radiation therapy program in a low-resource setting, pro

235 The risk of recurrence following radiation therapy remains high for a significant number

236 gion is rare, and the utility of surgery and radiation therapy remains unresolved.

237 combined with newer surgical techniques and radiation therapies, result in a collaborative multidisc

238 n therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates

239 tion of IRE to conventional chemotherapy and radiation therapy results in substantially prolonged sur

240 energy FUS with an ablative hypofractionated radiation therapy results in synergistic control of prim

241 mal radiation therapy or intensity-modulated radiation therapy/rotational techniques were used.

242 Patients treated with cranial radiation therapy (RT) are at risk for sensorineural hea

243 howed a lower survival rate in the high-dose radiation therapy (RT) arm (74 Gy) than in the low-dose

244 models examined change in IQ over time since radiation therapy (RT) by RT group, controlling for demo

245 To determine the optimal adjuvant radiation therapy (RT) dose following resection of local

246 Adjuvant radiation therapy (RT) has consistently demonstrated a r

247 ymphoma (HL) survivors treated with thoracic radiation therapy (RT) have impaired exercise tolerance

248 Increasing evidence suggests that ionizing radiation therapy (RT) in combination with checkpoint im

249 of preoperative chemotherapy with or without radiation therapy (RT) in the context of a phase III ran

250 Radiation therapy (RT) including external beam radiother

251 osis (RIPF) is a debilitating side effect of radiation therapy (RT) of several cancers including lung

252 The use of adjuvant radiation therapy (RT) to the primary site in Merkel cel

253 Until recently, radiation therapy (RT) was believed to mediate antineopl

254 Radiation therapy (RT), a major modality for treating lo

255 n patients with stage I disease treated with radiation therapy (RT), doses >/=30.6 Gy were associated

256 Cutaneous radiation therapy (RT)-associated breast angiosarcoma (A

257 h breast-conserving surgery without adjuvant radiation therapy (RT).

258 uable (because of disease progression before radiation therapy [RT], n = 9; refusal of surgery or RT,

259 Thus, TGFbeta is a fundamental regulator of radiation therapy's ability to generate an in situ tumor

260 the cost-effectiveness of stereotactic body radiation therapy (SBRT) versus radiofrequency ablation

261 se ablative radiation with stereotactic body radiation therapy (SBRT).

262 Radiation therapy seems to modestly increase certain ris

263 Radiation therapy-simulation CT images and diagnostic CT

264 (90)Y-microsphere selective internal radiation therapy (SIRT) is a valuable treatment in unre

265 cacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microsph

266 my may benefit from dose-intensified salvage radiation therapy (SRT) of the prostate bed.

267 We review growing evidence that radiation therapy targeted to the tumor can convert it i

268 ived combination chemotherapy in addition to radiation therapy than among those who received radiatio

269 Radiation therapy to the brain is a powerful tool in the

270 d CRT including cisplatin, fluorouracil, and radiation therapy to the primary tumor and regional lymp

271 and HIV infection received CRT: 45 to 54 Gy radiation therapy to the primary tumor and regional lymp

272 The radiation therapy-treated brain tumor group demonstrated

273 in tumor group were higher than those in the radiation therapy-treated brain tumor group for doses gr

274 III NSCLC treated on one of four prospective radiation therapy trials at two centers from 2004 to 201

275 alizing the extent of surgical resection and radiation therapy volumes.

276 Treatment regimen, hormone, or radiation therapy was not significantly associated with

277 (HR, 0.5; 95% CI, 0.3-0.9; P = .04), whereas radiation therapy was not.

278 Radiation therapy was provided for postchemotherapy stag

279 ne, or mastectomy followed by postmastectomy radiation therapy was recorded.

280 dence of late adverse events associated with radiation therapy was similar in the two groups.

281 Chemotherapy with or without external beam radiation therapy was the most frequently used treatment

282 eotactic radiosurgery (SRS), and whole-brain radiation therapy (WBRT).

283 n cancer-directed surgery, chemotherapy, and radiation therapy were combined (hazard ratio, 0.52).

284 use of four-dimensional CT and image-guided radiation therapy were encouraged but not necessary.

285 chedule; patients with prior chemotherapy or radiation therapy were excluded.

286 Iris melanoma patients treated with radiation therapy were imaged again after I-125 plaque b

287 Cancer-directed surgery, chemotherapy, and radiation therapy were independently associated with imp

288 Current evidence supports use of whole-brain radiation therapy when patients present with multiple BM

289 tumors to either metronomic chemotherapy or radiation therapy, where the degree of signal enhancemen

290 nd FL were mostly treated with external beam radiation therapy, whereas DLBCL, MCL, and high Ann Arbo

291 evealed that the addition of chemotherapy to radiation therapy, whether sequentially or concurrently,

292 treated first with combined chemotherapy and radiation therapy, who underwent MR imaging before final

293 Whether antiandrogen therapy with radiation therapy will further improve cancer control an

294 most frequent treatments were external beam radiation therapy with or without surgery (31.0%) and ri

295 C) patients administered intensity-modulated radiation therapy with simultaneous integrated boost (SI

296 The combination of local radiation therapy with TGFbeta neutralization offers a n

297 basis (eg, in target volume delineation for radiation therapy), with results of cytologic and/or his

298 the larynx by using endoscopic resection or radiation therapy, with either leading to similar outcom

299 Tissue Sarcoma) trial receiving preoperative radiation therapy without IGRT (P < .001).

300 CI, 157 patients with previous external beam radiation therapy (XRT) were matched 1:1 with 157 compar